Back to search

University of Minnesota

Engineering Safe and Efficacious Cell Therapies to Treat HIV

Abstract

dc:description.abstract

Over 39.9 million individuals are living with HIV worldwide, and although ART has greatly improved outcomes associated with HIV, it is not a cure. One barrier to the complete eradication of HIV is the reservoirs of HIV-infected cells that persist even during treatment with ART drugs. B-cell follicles within lymph nodes are one such reservoir, and this reservoir is created and persists largely due to the inability of cytotoxic immune cells to accumulate well within these regions, due to low expression of the follicular-homing receptor CXCR5. To overcome this barrier, our group engineers HIV-specific immune cell therapies that overexpress CXCR5 to direct migration to the B-cell follicles. Our group has previously shown that T cells engineered with HIV-specific Chimeric Antigen Receptor (CAR) molecules and CXCR5 can migrate to sites of viral replication in the B-cell follicles and kill HIV-infected cells in those sites. In this dissertation, I will discuss three projects that extend upon this foundation. The first describes the evaluation of novel HIV-targeting NK cell immunotherapies in an HIV-infected humanized mouse model. In this study, we uncovered an association between NK treatment timing and viral control, but failed to see migration of NK cells to sites of viral replication in the lymph nodes. The second project is an extension of the previous, in which NK cell therapies with improved lymphoid-targeting were evaluated in a rhesus macaque model of SIV. We found that lymph node homing was improved by transiently expressing CCR7 on the surface of engineered NK cells. In the final section, I will discuss previously undescribed alterations to the expression of surface receptors in cells engineered with CAR molecules. Here, I discovered that expression of certain surface receptors is consistently disrupted by engineering T cells, suggesting the importance of evaluating gene expression changes in cell therapies before clinical evaluation. These studies contribute to the wider knowledge base about engineering safe and efficacious cell therapies, and provide support for the use of NK cell therapies as long-acting HIV treatments.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Thron, Liliana K.

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Citation
Thron, Liliana K.. (2026). Engineering Safe and Efficacious Cell Therapies to Treat HIV. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/283159.

Chain of custody

source
Harvested from
University of Minnesota
Base URL
conservancy.umn.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Thron, Liliana K.. Engineering Safe and Efficacious Cell Therapies to Treat HIV. 2026. https://hdl.handle.net/11299/283159